Toggle Nav
Close
  • Menu
  • Setting

Dabrafenib (GSK2118436)

Catalog No.
B1407
Inhibitor of BRAF(V600) mutants
Grouped product items
SizePriceStock Qty
10mM (in 1mL DMSO)
$88.00
In stock
10mg
$77.00
In stock
50mg
$110.00
In stock
100mg
$154.00
In stock
For scientific research use only and should not be used for diagnostic or medical purposes.

Tel: +1-832-696-8203

Email: [email protected]

Worldwide Distributors

Background

Dabrafenib (GSK2118436; CAS 1195765-45-7) is a selective inhibitor targeting BRAF kinase mutations at positions V600E, V600K, and V600D. It functions by reversibly binding to the ATP-binding domain of mutant BRAF, suppressing aberrant MAPK pathway activation involved in cellular proliferation and differentiation. Reported inhibitory IC50 values are 0.5 nM (V600E), 0.6 nM (V600K), and 1.9 nM (V600D). Dabrafenib is employed widely in research involving BRAF-mutated metastatic melanoma, demonstrating reduced tumor size and improved patient survival outcomes.

Product Citation

Chemical Properties

Physical AppearanceA solid
StorageStore at -20°C
M.Wt519.56
Cas No.1195765-45-7
FormulaC23H20F3N5O2S2
Solubility≥26 mg/mL in DMSO; insoluble in H2O; ≥2.59 mg/mL in EtOH with gentle warming and ultrasonic
Chemical NameN-[3-[5-(2-aminopyrimidin-4-yl)-2-tert-butyl-1,3-thiazol-4-yl]-2-fluorophenyl]-2,6-difluorobenzenesulfonamide
SDFDownload SDF
Canonical SMILESCC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F
Shipping ConditionSmall Molecules with Blue Ice, Modified Nucleotides with Dry Ice.
General tips We do not recommend long-term storage for the solution, please use it up soon.

Protocol

Cell experiment [1, 2]:

Cell lines

B-RafV600E-driven melanoma lines, SKMEL28 and A375P F11, and colorectal carcinoma cells Colo205, HT29 cells

Preparation method

The solubility of this compound in DMSO is > 10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months.

Reacting condition

10 μM for 24 h

Applications

Dabrafenib effectively inhibited cell proliferation of B-RafV600E-driven melanoma lines, SKMEL28 and A375P F11 (IC50 = 3 and 8 nM, respectively), and colorectal carcinoma cells Colo205 (IC50 = 7 nM). Moreover, dabrafenib selectively inhibited RIP3 and inhibited RIP3-mediated necroptosis for HT29 cells.

Animal experiment [1, 2]:

Animal models

CD1 nu/nu mice bearing A375P F11 (B-RafV600E) tumors model

Dosage form

0.1, 1, 10, and 100 mg/kg, oral administration, once daily for 14 days or 300 mg/kg, 100 mg/kg dabrafenib (p.o.).

Applications

Dabrafenib dose-dependently inhibited tumor growth and reduced pERK levels in A375P F11 (B-RafV600E) human melanoma tissue in vivo. Additionally, dabrafenib alleviated acetaminophen-induced liver injury in mice.

Other notes

Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.

References:

1. Rheault, T. R., Stellwagen, J. C., Adjabeng, G. M., Hornberger, K. R., Petrov, K. G., Waterson, A. G., Dickerson, S. H., Mook, R. A., Jr., Laquerre, S. G., King, A. J., Rossanese, O. W., Arnone, M. R., Smitheman, K. N., Kane-Carson, L. S., Han, C., Moorthy, G. S., Moss, K. G. and Uehling, D. E. (2013) Discovery of Dabrafenib: A Selective Inhibitor of Raf Kinases with Antitumor Activity against B-Raf-Driven Tumors. ACS Med Chem Lett. 4, 358-362

2. Li, J. X., Feng, J. M., Wang, Y., Li, X. H., Chen, X. X., Su, Y., Shen, Y. Y., Chen, Y., Xiong, B., Yang, C. H., Ding, J. and Miao, Z. H. (2014) The B-Raf(V600E) inhibitor dabrafenib selectively inhibits RIP3 and alleviates acetaminophen-induced liver injury. Cell Death Dis. 5, e1278

Biological Activity

Description Dabrafenib (GSK2118436) is a inhibitor of mutant BRAFV600 specific with an IC50 value of 0.8 nM.
Targets B-Raf (V600E) B-Raf C-Raf      
IC50 0.8 nM 3.2 nM 5.0 nM      

Quality Control